ZEJULA Logo

COULD ZEJULA BE A NEXT STEP FOR YOUR ELIGIBLE PATIENTS?

Learn about ZEJULA: a once-daily, oral maintenance for women with newly diagnosed advanced ovarian cancer after complete or partial response to platinum-based chemotherapy.

Learn about ZEJULA: a once-daily, oral maintenance for women with newly diagnosed advanced ovarian cancer after complete or partial response to platinum-based chemotherapy.

  • VIDEO TRANSCRIPT | 1:30

    VO: Five months ago I was diagnosed with advanced ovarian cancer. Since then it’s been, well…overwhelming.

    TEXT ON SCREEN: N/A

     

    VO: I’ve got the scars and wigs to prove it. I’m almost done with chemo, but I am worried that the cancer will return.

    TEXT ON SCREEN: N/A

     

    VO: So I talked with my doctor and she told me about a treatment option that may help me move forward, by giving me more time without the cancer coming back.

    TEXT ON SCREEN: In a clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. Results may vary. The trial is still ongoing to see if patients live longer overall with treatment

     

    VO: It’s called ZEJULA. It’s not chemotherapy, it’s maintenance therapy.

    TEXT ON SCREEN: In a clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. Results may vary. The trial is still ongoing to see if patients live longer overall with treatment

     

    VO: Prescribed after response to chemotherapy, ZEJULA is proven to give you more time without cancer recurring.

    TEXT ON SCREEN: In a clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. Results may vary. The trial is still ongoing to see if patients live longer overall with treatment

     

    VO: It’s the only once-daily oral maintenance treatment.

    TEXT ON SCREEN: By prescription only.

     

    VO: ZEJULA is a prescription medicine for maintenance treatment of adults with advanced ovarian cancer used after a complete or partial response to treatment with platinum-based chemotherapy.

    TEXT ON SCREEN: Maintenance treatment for women with advanced ovarian, fallopian tube or primary peritoneal cancer, after complete or partial response to treatment with platinum-based chemotherapy.

     

    VO: ZEJULA may cause serious side effects such as bone marrow problems called MDS or a type of blood cancer called AML, which may lead to death.

    TEXT ON SCREEN: MDS – Myelodysplastic Syndrome. AML – Acute Myeloid Leukemia.

     

    VO: Symptoms of low blood cell counts may include weakness and can be a sign of serious bone marrow problems.

    TEXT ON SCREEN: Routine monitoring of blood counts is required.

     

    VO: Contact your doctor for new onset of bleeding, fever, or infection.

    TEXT ON SCREEN: New onset of bleeding could include bruising, bleeding more easily, or blood in urine or stool.

     

    VO: High blood pressure is common and can become serious.

    TEXT ON SCREEN: Routine monitoring of blood pressure and heart rate is required.

     

    VO: ZEJULA has been associated with PRES, a condition that affects the brain. Tell your doctor if you have headache, vision changes, confusion, or seizure.

    TEXT ON SCREEN: PRES – Posterior reversible encephalopathy syndrome

     

    VO: Tell your doctor about all your medical conditions and medications.

    TEXT ON SCREEN: Tell your doctor about all your medical conditions, including if you have liver problems and if you are pregnant or breastfeeding or plan to be.

     

    VO: Some common side effects include nausea, low blood cell counts, tiredness, constipation, muscle and back pain, headache, and trouble sleeping.

    TEXT ON SCREEN: These are not all the possible side effects of ZEJULA

     

    VO: You can take an active role in your treatment like I did.

    TEXT ON SCREEN: See price information at GSKforyou.com

     

    VO: Talk to your doctor about how ZEJULA may delay your cancer from recurring.

    TEXT ON SCREEN: See price information at GSKforyou.com

ONCE-DAILY ZEJULA

IS APPROVED FOR FIRST-LINE MAINTENANCE IN ADULTS WITH PLATINUM-RESPONSIVE ADVANCED OVARIAN CANCER REGARDLESS OF BIOMARKER STATUS.1

Learn more about how ZEJULA works and who it may help.

VISIT THE SITE

Reference: 1. ZEJULA (niraparib). Prescribing Information. GlaxoSmithKline; 2021.